---
schema_version: "secwatch.filing_event.v1"
accession: "0001640334-24-001396"
form_type: "8-K"
ticker: "LEXX"
cik: "0001348362"
company_name: "Lexaria Bioscience Corp."
filed_at: "2024-09-05T23:59:59+00:00"
generated_at: "2026-05-31T06:12:20.851412+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Lexaria appoints Richard Christopher as CEO; Bunka transitions to Chairman

## Summary
- Richard Christopher, 54, appointed CEO effective Aug 31, 2024; he also serves as interim CFO until new CFO is hired.
- Christopher receives 200,000 stock options at $3.92, base salary with 5% annual raises in 2025-26, and 50% of salary bonus target.
- Outgoing CEO Bunka's letter: $8.5M raised YTD 2024, market cap ~$60M, Phase 1b hypertension study expected H1 2025.
- GLP-1 R&D shows positive data; DehydraTECH-CBD outperforms in weight loss and blood sugar control in animal studies.
- Bunka remains Chairman and Executive Strategic Advisor; cites need for pharma operational expertise for execution phase.

## SEC filing metadata
- accession: 0001640334-24-001396
- form_type: 8-K
- ticker: LEXX
- cik: 0001348362
- company_name: Lexaria Bioscience Corp.
- filed_at: 2024-09-05T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1348362/000164033424001396/0001640334-24-001396-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1348362/000164033424001396/lxrp_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001640334-24-001396
- JSON: https://secwatch.observer/filing/0001640334-24-001396.json
- Plain text: https://secwatch.observer/filing/0001640334-24-001396.txt

## Key facts
- Executive change
  Richard Christopher was appointed as Chief Executive Officer at Lexaria Bioscience Corp..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: appointed Richard Christopher, age 54, to the position of Chief Executive Officer
  evidence_url: https://www.sec.gov/Archives/edgar/data/1348362/000164033424001396/0001640334-24-001396-index.htm
- Executive change
  Christopher Bunka changed role as Chairman of the Board at Lexaria Bioscience Corp..
  - Role: Chairman of the Board
  source text: replacing Christopher Bunka who will remain as the Company’s Chairman of the Board and as a strategic advisor
  evidence_url: https://www.sec.gov/Archives/edgar/data/1348362/000164033424001396/0001640334-24-001396-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.